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Abstract
We report two cases of "uterine leiomyoma with tubules" as a new pathological entity. Since these
are biphasic neoplasms (composed by epithelial and mesenchimal elements), the differential
diagnosis is between mixed mullerian tumors and uterine tumors resembling ovarian sex cord
tumors (UTROSCTs). In the differential diagnosis, the mixed mullerian tumors are easily excluded
because of histological and immunohistochemical features. UTROSCTs are similar to the lesions
we reported, and the differential diagnosis requires positivity for some immunohistochemical
markers as inhibin, CD99, calretinin, Melan-A. Our conclusions are that to perform a diagnosis of
UTROSCT at least two immunohistochemical marker have to be expressed; in the present case
they didn't, so we call the lesion "leiomyoma with tubules".
Background
The presence of cellular structures with epithelial-like or
sex cord-like appearance embedded in mesenchimal nod-
ular circumscribed tissue is an unusual finding, and it may
cause some difficulties in making the diagnosis or in clas-
sifying the lesion. In the present paper we describe the
clinicopathological features of two neoplasms composed
by tubules and gland-like epithelial structures and
smooth muscular tissue. Histologically, the lesion simu-
lated uterine tumors resembling ovarian sex cord tumors
(UTROSCTs), but the immunophenotype was not consist-
ent with true sex-cord differentiation. The diagnosis con-
sequently had been only descriptive: "leiomyoma with
tubules".
Case presentation
Case 1
In July 1997 a 55-years-old postmenopausal woman pre-
sented with recurrent vaginal bleeding. Ultrasonography
preoperative diagnosis was uterine leiomyoma. The
patient underwent hysterectomy and bilateral salpingo-
oophorectomy. Grossly the uterus weighed 120 g and
measured 10 × 5 × 5 cm. On the cut surface the uterine
wall, showed a submucosal, solid, gray nodule of 3.5 cm
in diameter.
Case 2
In April 1998 a 64-years-old postmenopausal woman pre-
sented with episodic vaginal bleeding. Ultrasonography
revealed a mass located within the left wall of the uterus.
A standard total abdominal hysterectomy and bilateral
salpingo-oophorectomy was performed. On the cut sur-
face an 1,9 cm maximum diameter intramural nodule was
localized within the anterior wall and was focally firm and
white in appearance with other softer yellowish colored
areas.
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Three blocks for each case was selected for immunohisto-
chemistry. Staining was performed using the following
antibodies:
CAM5.2 low-weight keratin, AE1/AE3 high-weight kera-
tin, vimentin, desmin, caldesmon, inhibin, estrogen
receptor (ER), CD99, CD10, calretinin, progesterone
receptor (PgR) and Melan-A. Immunostaining was carried
out using appropriate positive controls. Primary antibody
was detected using a sensitive Strept-ABC technique with
diaminobenzidine development. All staining were per-
formed with an automatic immunostainer (Biogenex
Optimax).
Cases were scored as negative, focally positive (<50% cells
staining) or diffusely positive (> 50% cells staining)
Histologically, both neoplasms were situated in the myo-
metrium without involvement of the endometrium. They
were well circumscribed, exhibited similar features and
were mainly composed of sweeping and intersecting fasci-
cles of smooth muscle cells surrounding a diffuse prolifer-
ation of tubular and gland-like structures lined by plump
cells with indistinct cytoplasm (Fig. 1). Necrosis, nuclear
pleomorphism or mitoses were not observed within the
tumors.
Smooth muscle elements and tubular structures were
weakly immunoreactive for high and low molecular kerat-
ins (AE1/AE3 and CAM5.2) and calretinin; caldesmon
and desmin were strongly positive only in the smooth
muscle component. Staining for inhibin, CD99, CD10
and Melan-A were negative. Glandular structures showed
nuclear cells positivity for PgR, while ER immunoreactiv-
ity was expressed into the stromal cells and glandular ele-
ments (Fig. 2). The case was sent for consultation to Prof.
Hildebrandt, Prof. Hendrickson, Prof. Kempson of Labo-
ratory of Surgical Pathology Stanford Health Services, Cal-
ifornia, USA, that performed the diagnosis of
"Leiomyoma with tubules".
The diagnosis "leiomyoma with tubules was performed
for both cases.
Discussion and conclusion
The differential diagnosis of the biphasic mesenchimal
uterine neoplasms could be difficult for the pathologist:
after exclusion of the mixed mullerian tumors, the prob-
lems arise in the distinction of UTROSCTs versus leiomy-
oma with tubules. UTROSCTs were originally classified by
Clement and Scully [1] into two groups. Type I were char-
acterized by endometrial stromal tumors with sex cord-
like elements (ESTSCLE: Group I tumors) while in type II
tumors the sex cord-like elements predominated (UTRO-
SCT: Group II). Although relatively few cases have been
reported with long term follow-up, type I tumors showed
a propensity to recur or metastatize, whereas type II fol-
lowed a benign course. UTROSCT are placed in the mis-
cellaneous category in the most recent World Health
Organization classification [2], without any distinction
between the different prognostic courses. Since the origi-
nal description of UTROSCT several studies have
attempted to further characterize this unusual group of
uterine neoplasms with variable ultrastructural and
Case1. Into the mesenchymal component it is appreciable  the glandular elements (Hematoxylin & Eosin, 100×) Figure 1
Case1. Into the mesenchymal component it is appreciable 
the glandular elements (Hematoxylin & Eosin, 100×).
Case2. Expression of antibody anti-estrogen receptor (Estro- gen receptor, 100×) Figure 2
Case2. Expression of antibody anti-estrogen receptor (Estro-
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immunohistochemical evidence supporting myogenic
[3], epithelial [9,10] and sex cord differentiation [11-17].
In the present study we included an extended panel of
antibodies inclusive of the identified markers of sex cord
differentiation as reported in literature for the immuno-
histochemical analysis of UTROSCTs because the patho-
logical features of the neoplasms described by us were
reminiscent of ovarian sex cord tumor. The immunohisto-
chemical profile of our cases were inconsistent with the
previously described cases. They were negative for
inhibin, CD99, CD10, calretinin and Melan A, weakly
positive for Keratins in both sex cord areas and in stromal
cells and immunoreactive for ER and PgR. In the follow-
ing paragraphs we discuss the results of immunohisto-
chemical results and compare these with previous studies
in literature.
A review of the 47 cases of uterine tumors with sex cord
differentiation reported in literature [11-14,16,17,19,20]
shows inhibin expression in 17.6% (3/17) and 40% (12/
30) of type I and type II tumors, respectively. These data
are in contrast with the accurate diagnostic value of
inhibin described in ovarian sex cord stromal tumors [9].
Therefore inhibin negativity should not preclude a diag-
nosis of UTROSCTs [25].
Of the previously reported UTROSCTs CD99 positivity
was detected in five of five cases described by Baker et al
[12] similar to Krishnamurthy et al [15] who found posi-
tivity in seven of seven UTROSCT. Oliva et al [20]
reported CD99 positivity in four of seven cases and CD99
was detected in the single case report described by Moti-
wala et al [26], Oztekin et al [21] and Sutak et al [22]. Our
neoplasms were not immunoreactive for CD99, although
this antibody seems to be the most frequent marker of sex
cord differentiation in UTROSCTs, more useful than
inhibin.
CD99 expression tends to correlate with inhibin and it is
typically confined to similar cell types in the individual
tumors.
Calretinin is another marker useful and widely utilized for
diagnosis of sex-cord tumors, and its value as marker of
this group of neoplasms is well documented. In literature,
to the best of our knowledge, description of calretinin
immunoreactivity in UTROSCT is reported in 11 cases
[13,18,22,23]: calretinin has been described positive in
67% (2/3) and 87.5% (7/8) type I and type II cases,
respectively. The limited number of the reported cases
don't give any conclusive information regarding the role
of this marker in UTROSCTs diagnosis.
Keratins (high molecular weight AE1/3 and low molecu-
lar weight CAM 5.2) are usually used as a marker of epi-
thelial differentiation, but it has been shown that some
mesenchymal tumors may express this antigene, too. In
the series of Oliva [20] and of Krishnamurthy [15], most
of UTROSCTs stained for keratins (five of seven cases), a
frequency similarly observed in other studies.
All of our cases exhibited nuclear immunoreactivity for
estrogen receptors (ER) and progesterone receptors (PgR)
as demonstrated in other studies. Seven examples of
Clement and Scully's type II uterine tumors reported by
Krishnamurthy et al [15] were found to be positive for ER
and PgR in the gland-like formations. In the report of Irv-
ing et al [23] three of five cases of UTROSCTs showed ER
immunoreactivity, although in two cases restricted to the
sex cord elements, while four cases were PgR positive. In
the case report diagnosed by Sutak et al as UTROSCT [22]
staining for progesterone was negative. Our results are
partially concordant with the data present in the litera-
ture, but we need further studies to determining the value
of ER and PgR in the characterization of this polypheno-
typic group of neoplasms.
H-caldesmon is useful to characterize the myoid differen-
tiation but is usually negative in UTROSCTs although a
component of smooth muscle can be seen in these neo-
plasms. Some authors suggest that cells with myoid
appearance are an integral component of the tumor while
others are uncertain whether these foci are entrapped
smooth muscle [28].
Studies of Melan-A expression in UTROSCTs are limited
to 17 cases [[15,17,24],29]. Of the previously reported
type II – UTROSCTs 6 of 14 have been positive with
Melan-A, whereas no positivity was demonstrated in 3
type I cases-ESTSCLE [15,17,23,24]. The positive findings
of Melan-A supports a specialized gonadal stromal pheno-
type.
The literature review highlights that there aren't uniform
or distinct immunohistological findings which character-
ize UTROSCT category. In the WHO classification UTRO-
SCTs are classified as "sex cord – like tumors" in the
"miscellaneous category". Nogales e Tavassoli think that
these tumors are "histologically and immunohistochemi-
cally identical to ovarian steroid-producing cells, being
strongly positive for alpha-inhibin, calretinin and CD99"
[2], but the literature data contrast this affirmation. Con-
sequently it may be problematic the diagnosis of a lesion
which has histological features of UTROSCTs, without the
immunohistochemical features, described before. In our
cases, we preferred a descriptive nomenclature. The
stroma of the lesions showed positivity for desmin,
smooth muscle actin and caldesmon, confirming theInternational Seminars in Surgical Oncology 2008, 5:15 http://www.issoonline.com/content/5/1/15
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smooth muscular differentiation of the stromal neoplastic
component. In our lesions all markers of sex cord differ-
entiation were absent, and so we preferred to classify the
lesion as "leiomyoma with tubules". In according to diag-
nosis of Prof. Hildebrandt, Prof. Hendrickson, Prof.
Kempson, we can conclude that a diagnosis based on his-
tological features without any specification of the pheno-
type should be preferable in similar lesions when all the
immunohistochemical markers for sex cord tumors are
absent. The exact diagnosis is necessary for clinical in
order to establish adequate prognostic criteria and opti-
mal management of the lesion.
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